Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.


Journal

The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309

Informations de publication

Date de publication:
12 2019
Historique:
received: 27 04 2019
revised: 19 07 2019
accepted: 29 07 2019
entrez: 9 11 2019
pubmed: 9 11 2019
medline: 13 6 2020
Statut: ppublish

Résumé

Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into the causes of Parkinson's disease. We did a meta-analysis of 17 datasets from Parkinson's disease GWAS available from European ancestry samples to nominate novel loci for disease risk. These datasets incorporated all available data. We then used these data to estimate heritable risk and develop predictive models of this heritability. We also used large gene expression and methylation resources to examine possible functional consequences as well as tissue, cell type, and biological pathway enrichments for the identified risk factors. Additionally, we examined shared genetic risk between Parkinson's disease and other phenotypes of interest via genetic correlations followed by Mendelian randomisation. Between Oct 1, 2017, and Aug 9, 2018, we analysed 7·8 million single nucleotide polymorphisms in 37 688 cases, 18 618 UK Biobank proxy-cases (ie, individuals who do not have Parkinson's disease but have a first degree relative that does), and 1·4 million controls. We identified 90 independent genome-wide significant risk signals across 78 genomic regions, including 38 novel independent risk signals in 37 loci. These 90 variants explained 16-36% of the heritable risk of Parkinson's disease depending on prevalence. Integrating methylation and expression data within a Mendelian randomisation framework identified putatively associated genes at 70 risk signals underlying GWAS loci for follow-up functional studies. Tissue-specific expression enrichment analyses suggested Parkinson's disease loci were heavily brain-enriched, with specific neuronal cell types being implicated from single cell data. We found significant genetic correlations with brain volumes (false discovery rate-adjusted p=0·0035 for intracranial volume, p=0·024 for putamen volume), smoking status (p=0·024), and educational attainment (p=0·038). Mendelian randomisation between cognitive performance and Parkinson's disease risk showed a robust association (p=8·00 × 10 These data provide the most comprehensive survey of genetic risk within Parkinson's disease to date, to the best of our knowledge, by revealing many additional Parkinson's disease risk loci, providing a biological context for these risk factors, and showing that a considerable genetic component of this disease remains unidentified. These associations derived from European ancestry datasets will need to be followed-up with more diverse data. The National Institute on Aging at the National Institutes of Health (USA), The Michael J Fox Foundation, and The Parkinson's Foundation (see appendix for full list of funding sources).

Sections du résumé

BACKGROUND
Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into the causes of Parkinson's disease.
METHODS
We did a meta-analysis of 17 datasets from Parkinson's disease GWAS available from European ancestry samples to nominate novel loci for disease risk. These datasets incorporated all available data. We then used these data to estimate heritable risk and develop predictive models of this heritability. We also used large gene expression and methylation resources to examine possible functional consequences as well as tissue, cell type, and biological pathway enrichments for the identified risk factors. Additionally, we examined shared genetic risk between Parkinson's disease and other phenotypes of interest via genetic correlations followed by Mendelian randomisation.
FINDINGS
Between Oct 1, 2017, and Aug 9, 2018, we analysed 7·8 million single nucleotide polymorphisms in 37 688 cases, 18 618 UK Biobank proxy-cases (ie, individuals who do not have Parkinson's disease but have a first degree relative that does), and 1·4 million controls. We identified 90 independent genome-wide significant risk signals across 78 genomic regions, including 38 novel independent risk signals in 37 loci. These 90 variants explained 16-36% of the heritable risk of Parkinson's disease depending on prevalence. Integrating methylation and expression data within a Mendelian randomisation framework identified putatively associated genes at 70 risk signals underlying GWAS loci for follow-up functional studies. Tissue-specific expression enrichment analyses suggested Parkinson's disease loci were heavily brain-enriched, with specific neuronal cell types being implicated from single cell data. We found significant genetic correlations with brain volumes (false discovery rate-adjusted p=0·0035 for intracranial volume, p=0·024 for putamen volume), smoking status (p=0·024), and educational attainment (p=0·038). Mendelian randomisation between cognitive performance and Parkinson's disease risk showed a robust association (p=8·00 × 10
INTERPRETATION
These data provide the most comprehensive survey of genetic risk within Parkinson's disease to date, to the best of our knowledge, by revealing many additional Parkinson's disease risk loci, providing a biological context for these risk factors, and showing that a considerable genetic component of this disease remains unidentified. These associations derived from European ancestry datasets will need to be followed-up with more diverse data.
FUNDING
The National Institute on Aging at the National Institutes of Health (USA), The Michael J Fox Foundation, and The Parkinson's Foundation (see appendix for full list of funding sources).

Identifiants

pubmed: 31701892
pii: S1474-4422(19)30320-5
doi: 10.1016/S1474-4422(19)30320-5
pmc: PMC8422160
mid: NIHMS1735188
pii:
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

1091-1102

Subventions

Organisme : Medical Research Council
ID : MR/K01417X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L501542/1
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : Parkinson's UK
ID : G-0907
Pays : United Kingdom
Organisme : Parkinson's UK
ID : H-1703
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700943
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026004/1
Pays : United Kingdom
Organisme : Parkinson's UK
ID : K-1501
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : RF1 AG058476
Pays : United States
Organisme : Medical Research Council
ID : G0701075
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901254
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1100643
Pays : United Kingdom

Investigateurs

Astrid D Adarmes-Gómez (AD)
Miquel Aguilar (M)
Akbota Aitkulova (A)
Vadim Akhmetzhanov (V)
Roy N Alcalay (RN)
Ignacio Alvarez (I)
Victoria Alvarez (V)
Sara Bandres-Ciga (S)
Francisco Javier Barrero (FJ)
Jesús Alberto Bergareche Yarza (JA)
Inmaculada Bernal-Bernal (I)
Kimberley Billingsley (K)
Cornelis Blauwendraat (C)
Marta Blazquez (M)
Marta Bonilla-Toribio (M)
Juan A Botía (JA)
María Teresa Boungiorno (MT)
Jose Bras (J)
Alexis Brice (A)
Kathrin Brockmann (K)
Vivien Bubb (V)
Dolores Buiza-Rueda (D)
Ana Cámara (A)
Fátima Carrillo (F)
Mario Carrión-Claro (M)
Debora Cerdan (D)
Viorica Chelban (V)
Jordi Clarimón (J)
Carl Clarke (C)
Yaroslau Compta (Y)
Mark R Cookson (MR)
Jean-Christophe Corvol (JC)
David W Craig (DW)
Fabrice Danjou (F)
Monica Diez-Fairen (M)
Oriol Dols-Icardo (O)
Jacinto Duarte (J)
Raquel Duran (R)
Francisco Escamilla-Sevilla (F)
Valentina Escott-Price (V)
Mario Ezquerra (M)
Faraz Faghri (F)
Cici Feliz (C)
Manel Fernández (M)
Rubén Fernández-Santiago (R)
Steven Finkbeiner (S)
Thomas Foltynie (T)
Ziv Gan-Or (Z)
Ciara Garcia (C)
Pedro García-Ruiz (P)
Thomas Gasser (T)
J Raphael Gibbs (JR)
Maria Jose Gomez Heredia (MJ)
Pilar Gómez-Garre (P)
Manuel Menéndez González (MM)
Isabel Gonzalez-Aramburu (I)
Sebastian Guelfi (S)
Rita Guerreiro (R)
John Hardy (J)
Sharon Hassin-Baer (S)
Dena G Hernandez (DG)
Peter Heutink (P)
Janet Hoenicka (J)
Peter Holmans (P)
Henry Houlden (H)
Jon Infante (J)
Hirotaka Iwaki (H)
Silvia Jesús (S)
Adriano Jimenez-Escrig (A)
Gulnaz Kaishybayeva (G)
Rauan Kaiyrzhanov (R)
Altynay Karimova (A)
Demis A Kia (DA)
Kerri J Kinghorn (KJ)
Sulev Koks (S)
Lynne Krohn (L)
Jaime Kulisevsky (J)
Miguel A Labrador-Espinosa (MA)
Hampton L Leonard (HL)
Suzanne Lesage (S)
Patrick Lewis (P)
Jose Luis Lopez-Sendon (JL)
Ruth Lovering (R)
Steven Lubbe (S)
Codrin Lungu (C)
Daniel Macias (D)
Kari Majamaa (K)
Claudia Manzoni (C)
Juan Marín (J)
Johan Marinus (J)
Maria Jose Marti (MJ)
Maria Martinez (M)
Irene Martínez Torres (I)
Juan Carlos Martínez-Castrillo (JC)
Marina Mata (M)
Niccolo E Mencacci (NE)
Carlota Méndez-Del-Barrio (C)
Ben Middlehurst (B)
Adolfo Mínguez (A)
Pablo Mir (P)
Kin Y Mok (KY)
Huw R Morris (HR)
Esteban Muñoz (E)
Mike A Nalls (MA)
Derek Narendra (D)
Alastair J Noyce (AJ)
Oluwadamilola O Ojo (OO)
Njideka U Okubadejo (NU)
Ana Gorostidi Pagola (AG)
Pau Pastor (P)
Francisco Perez Errazquin (F)
Teresa Periñán-Tocino (T)
Lasse Pihlstrom (L)
Helene Plun-Favreau (H)
John Quinn (J)
Lea R'Bibo (L)
Xylena Reed (X)
Elisabet Mondragon Rezola (EM)
Mie Rizig (M)
Patrizia Rizzu (P)
Laurie Robak (L)
Antonio Sanchez Rodriguez (AS)
Guy A Rouleau (GA)
Javier Ruiz-Martínez (J)
Clara Ruz (C)
Mina Ryten (M)
Dinara Sadykova (D)
Sonja W Scholz (SW)
Sebastian Schreglmann (S)
Claudia Schulte (C)
Manu Sharma (M)
Chingiz Shashkin (C)
Joshua M Shulman (JM)
María Sierra (M)
Ari Siitonen (A)
Javier Simón-Sánchez (J)
Andrew B Singleton (AB)
Esther Suarez-Sanmartin (E)
Pille Taba (P)
Cesar Tabernero (C)
Manuela X Tan (MX)
Juan Pablo Tartari (JP)
Cristina Tejera-Parrado (C)
Mathias Toft (M)
Eduard Tolosa (E)
Daniah Trabzuni (D)
Francesc Valldeoriola (F)
Jacobus J van Hilten (JJ)
Kendall Van Keuren-Jensen (K)
Laura Vargas-González (L)
Lydia Vela (L)
Francisco Vives (F)
Nigel Williams (N)
Nicholas W Wood (NW)
Nazira Zharkinbekova (N)
Zharkyn Zharmukhanov (Z)
Elena Zholdybayeva (E)
Alexander Zimprich (A)
Pauli Ylikotila (P)
Lisa M Shulman (LM)
Rainer von Coelln (R)
Stephen Reich (S)
Joseph Savitt (J)
Michelle Agee (M)
Babak Alipanahi (B)
Adam Auton (A)
Robert K Bell (RK)
Katarzyna Bryc (K)
Sarah L Elson (SL)
Pierre Fontanillas (P)
Nicholas A Furlotte (NA)
Karen E Huber (KE)
Barry Hicks (B)
Ethan M Jewett (EM)
Yunxuan Jiang (Y)
Aaron Kleinman (A)
Keng-Han Lin (KH)
Nadia K Litterman (NK)
Jennifer C McCreight (JC)
Matthew H McIntyre (MH)
Kimberly F McManus (KF)
Joanna L Mountain (JL)
Elizabeth S Noblin (ES)
Carrie A M Northover (CAM)
Steven J Pitts (SJ)
G David Poznik (GD)
J Fah Sathirapongsasuti (JF)
Janie F Shelton (JF)
Suyash Shringarpure (S)
Chao Tian (C)
Joyce Tung (J)
Vladimir Vacic (V)
Xin Wang (X)
Catherine H Wilson (CH)
Tim Anderson (T)
Steven Bentley (S)
John Dalrymple-Alford (J)
Javed Fowdar (J)
Jacob Gratten (J)
Glenda Halliday (G)
Anjali K Henders (AK)
Ian Hickie (I)
Irfahan Kassam (I)
Martin Kennedy (M)
John Kwok (J)
Simon Lewis (S)
George Mellick (G)
Grant Montgomery (G)
John Pearson (J)
Toni Pitcher (T)
Julia Sidorenko (J)
Peter A Silburn (PA)
Costanza L Vallerga (CL)
Peter M Visscher (PM)
Leanne Wallace (L)
Naomi R Wray (NR)
Angli Xue (A)
Jian Yang (J)
Futao Zhang (F)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Lancet. 2011 Feb 19;377(9766):641-9
pubmed: 21292315
Cell. 2018 Aug 9;174(4):1015-1030.e16
pubmed: 30096299
Bioinformatics. 2015 May 1;31(9):1466-8
pubmed: 25550326
Nat Protoc. 2015 Oct;10(10):1556-66
pubmed: 26379229
Science. 1996 Nov 15;274(5290):1197-9
pubmed: 8895469
Nat Genet. 2006 Feb;38(2):209-13
pubmed: 16415888
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Lancet Neurol. 2006 Nov;5(11):911-6
pubmed: 17052657
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Lancet Neurol. 2015 Oct;14(10):1002-9
pubmed: 26271532
Nat Genet. 2014 Sep;46(9):989-93
pubmed: 25064009
Nat Genet. 2019 Mar;51(3):404-413
pubmed: 30617256
Nature. 2006 Aug 24;442(7105):920-4
pubmed: 16862115
Nature. 2015 Apr 9;520(7546):224-9
pubmed: 25607358
Hum Mol Genet. 2012 Nov 15;21(22):4996-5009
pubmed: 22892372
Nat Genet. 2016 May;48(5):481-7
pubmed: 27019110
PLoS Med. 2016 Jun 21;13(6):e1001976
pubmed: 27327646
Nat Genet. 2015 Mar;47(3):291-5
pubmed: 25642630
Nat Genet. 2015 Nov;47(11):1236-41
pubmed: 26414676
Mov Disord. 2015 May;30(6):850-4
pubmed: 25778492
Mov Disord. 2019 Apr;34(4):460-468
pubmed: 30675927
PLoS Genet. 2018 May 24;14(5):e1007329
pubmed: 29795570
Nat Genet. 2012 Mar 18;44(4):369-75, S1-3
pubmed: 22426310
Genet Epidemiol. 2017 Feb;41(2):145-151
pubmed: 27990689
Nucleic Acids Res. 2017 Jul 3;45(W1):W130-W137
pubmed: 28472511
Genome Biol. 2017 May 16;18(1):86
pubmed: 28506277
Nat Commun. 2018 Mar 2;9(1):918
pubmed: 29500431
Neurology. 2007 Jan 30;68(5):384-6
pubmed: 17082464
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
PLoS Genet. 2010 Feb 26;6(2):e1000864
pubmed: 20195508
Am J Hum Genet. 2017 Jan 5;100(1):40-50
pubmed: 27989323
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
Nat Genet. 2018 Aug;50(8):1112-1121
pubmed: 30038396
PLoS One. 2014 Sep 08;9(9):e106676
pubmed: 25198429
Am J Hum Genet. 2012 Jun 8;90(6):1102-7
pubmed: 22608501
Nat Commun. 2018 Jun 11;9(1):2282
pubmed: 29891976
Brain. 2017 Dec 1;140(12):3191-3203
pubmed: 29140481
Nat Genet. 2017 Oct;49(10):1511-1516
pubmed: 28892059
Am J Hum Genet. 2012 Aug 10;91(2):224-37
pubmed: 22863193
Nature. 2018 Oct;562(7726):210-216
pubmed: 30305740
PLoS Genet. 2011 Jun;7(6):e1002142
pubmed: 21738488

Auteurs

Mike A Nalls (MA)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Glen Echo, MD, USA. Electronic address: mike@datatecnica.com.

Cornelis Blauwendraat (C)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Costanza L Vallerga (CL)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.

Karl Heilbron (K)

23andMe, Sunnyvale, CA, USA.

Sara Bandres-Ciga (S)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Diana Chang (D)

Department of Human Genetics, Genentech, South San Francisco, CA, USA.

Manuela Tan (M)

Department of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, UK; Department of Clinical and Movement Neuroscience and UCL Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK.

Demis A Kia (DA)

Department of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, UK; Department of Clinical and Movement Neuroscience and UCL Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK.

Alastair J Noyce (AJ)

Department of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, UK; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Angli Xue (A)

Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.

Jose Bras (J)

Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, London, UK; Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA.

Emily Young (E)

Department of Neurology, Baylor College of Medicine, Houston, TX, USA.

Rainer von Coelln (R)

Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.

Javier Simón-Sánchez (J)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.

Claudia Schulte (C)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.

Manu Sharma (M)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.

Lynne Krohn (L)

Department of Human Genetics, McGill University, Montreal, QC, Canada; Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

Lasse Pihlstrøm (L)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Ari Siitonen (A)

Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland; Department of Neurology and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Hirotaka Iwaki (H)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Glen Echo, MD, USA; The Michael J Fox Foundation, New York, NY, USA.

Hampton Leonard (H)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Data Tecnica International, Glen Echo, MD, USA.

Faraz Faghri (F)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Department of Computer Science, University of Illinois Urbana-Champaign, Champaign, IL, USA.

J Raphael Gibbs (JR)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Dena G Hernandez (DG)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Sonja W Scholz (SW)

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA.

Juan A Botia (JA)

Department of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, UK; Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, Spain.

Maria Martinez (M)

Institut national de la santé et de la recherche médicale Unité mixte de recherche 1220, Toulouse, France; Paul Sabatier University, Toulouse, France.

Jean-Christophe Corvol (JC)

Institut national de la santé et de la recherche médicale U1127, CNRS UMR 7225, Paris, France; Sorbonne Université centre national de la recherche médicale, unité mixte de recherche 1127, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France; Institut du Cerveau et de la Moelle épinière, Paris, France.

Suzanne Lesage (S)

Institut national de la santé et de la recherche médicale U1127, CNRS UMR 7225, Paris, France; Sorbonne Université centre national de la recherche médicale, unité mixte de recherche 1127, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France; Institut du Cerveau et de la Moelle épinière, Paris, France.

Joseph Jankovic (J)

Department of Neurology, Baylor College of Medicine, Houston, TX, USA.

Lisa M Shulman (LM)

Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.

Margaret Sutherland (M)

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.

Pentti Tienari (P)

Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland; Helsinki University Hospital, Helsinki, Finland.

Kari Majamaa (K)

Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland; Department of Neurology and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Mathias Toft (M)

Department of Neurology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Ole A Andreassen (OA)

Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Jebsen Centre for Psychosis Research, University of Oslo, Oslo, Norway.

Tushar Bangale (T)

Department of Human Genetics, Genentech, South San Francisco, CA, USA.

Alexis Brice (A)

Institut national de la santé et de la recherche médicale U1127, CNRS UMR 7225, Paris, France; Sorbonne Université centre national de la recherche médicale, unité mixte de recherche 1127, Paris, France; Assistance Publique Hôpitaux de Paris, Paris, France; Institut du Cerveau et de la Moelle épinière, Paris, France.

Jian Yang (J)

Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.

Ziv Gan-Or (Z)

Department of Human Genetics, McGill University, Montreal, QC, Canada; Montreal Neurological Institute, McGill University, Montreal, QC, Canada; Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.

Thomas Gasser (T)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.

Peter Heutink (P)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.

Joshua M Shulman (JM)

Department of Neurology, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.

Nicholas W Wood (NW)

Department of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, UK; Department of Clinical and Movement Neuroscience and UCL Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK.

David A Hinds (DA)

23andMe, Sunnyvale, CA, USA.

John A Hardy (JA)

Department of Molecular Neuroscience, UCL Queen Square Institute of Neurology, London, UK.

Huw R Morris (HR)

Department of Clinical and Movement Neuroscience and UCL Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK.

Jacob Gratten (J)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia; Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.

Peter M Visscher (PM)

Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.

Robert R Graham (RR)

Department of Human Genetics, Genentech, South San Francisco, CA, USA.

Andrew B Singleton (AB)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH